Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$75.50 USD

75.50
528,405

0.00 (0.00%)

Updated Jun 4, 2024 11:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Cardiovascular Systems Set to Present LIBERTY 360 Outcome

by Zacks Equity Research

This study outcome is expected to be a major stride forward in Cardiovascular Systems' (CSII) endeavor to offer treatment to patients of multi-level peripheral artery disease (PAD).

Boston Scientific Rides on New Products Amid Dull Pacer Sales

by Zacks Equity Research

Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.

    Kalyan Nandy headshot

    Top Analyst Reports: Amgen, Uber, Mondelez & More

    by Kalyan Nandy

    Today's Research Daily features updated research reports on 16 major stocks, including Amgen (AMGN), Uber (UBER) and Mondelez (MDLZ).

    Urmimala Biswas headshot

    4 Medical Product Stocks Set to Beat This Earnings Season

    by Urmimala Biswas

    Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

    Boston Scientific (BSX) Q2 Earnings Top on Growth in All Lines

    by Zacks Equity Research

    Boston Scientific's (BSX) revenue strength across all business lines and geographies raises investors' optimism on the stock.

    Boston Scientific (BSX) Surpasses Q2 Earnings Estimates

    by Zacks Equity Research

    Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and -0.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

    What's in Store for Boston Scientific's (BSX) Q2 Earnings?

    by Zacks Equity Research

    We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.

    Urmimala Biswas headshot

    Will USTR's 25% Tariff Exemption Spell Relief for MedTech?

    by Urmimala Biswas

    In the wake of the U.S. tariff and Chinese retaliation, the MedTech industry players (with production houses in China) are facing huge bottom line pressure.

    Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline

    by Zacks Equity Research

    Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Sreyoshi Mukherjee headshot

    US-India Trade Tensions Rise: 3 Stocks in the Line of Fire

    by Sreyoshi Mukherjee

    As India moves toward self-sufficiency, U.S. MedTech bigwigs fret over possible losses.

    Urmimala Biswas headshot

    Tap AI-Powered Medical Device Stocks as FDA Bolsters SaMD

    by Urmimala Biswas

    The whole MedTech community finds a reason to cheer over with the FDA's recent proposal for Software as a Medical Device.

    The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Bank of America, Eli Lilly, Boston Scientific, Schwab and Advanced Micro Devices

    Boston Scientific's Global Growth Robust Amid Currency Woe

    by Zacks Equity Research

    Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.

    Mark Vickery headshot

    Top Stock Reports for Bank of America, Eli Lilly & Boston Scientific

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Eli Lilly (LLY) and Boston Scientific (BSX).

    Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout

    by Zacks Equity Research

    The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.

    Edwards Lifesciences Recalls Heart Device on Balloon Rupture

    by Zacks Equity Research

    Shares of Edwards Lifesciences (EW) decline post product recall news.

    Stock Market News for Jul 3, 2019

    by Zacks Equity Research

    Wall Street registered decent gains on Tuesday.

    Varian to Acquire Boston Scientific's Embolic Bead Products

    by Zacks Equity Research

    Varian (VAR) expects the buyout to prove accretive to its fiscal 2020 reported and adjusted earnings per share.

    Boston Scientific Strong on Growth Goals and Future Launches

    by Zacks Equity Research

    This long-range strategy will aid Boston Scientific (BSX) to deliver a solid financial footing across its MedSurg, Rhythm and Neuro plus Cardiovascular segments.

    Urmimala Biswas headshot

    CMS' Final Verdict on TAVR: A Boon or Bane for MedTech?

    by Urmimala Biswas

    While the industry bigwigs are keen to welcome the new CMS ruling, companies like Heart Valve Voice US are not lagging to pen their resistance against a revised policy.

    Urmimala Biswas headshot

    Near-Term Outlook for Medical Instruments Industry Bleak

    by Urmimala Biswas

    Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.

    Boston Scientific's New Products, Acquisitions Boost Growth

    by Zacks Equity Research

    Boston Scientific (BSX) is pulling out all the stops to strengthen its core businesses as well as invest in new technologies and the overseas markets.

    Boston Scientific (BSX) Announces Vertiflex Acquisition

    by Zacks Equity Research

    The acquisition is in sync with Boston Scientific's (BSX) strategy of expanding pain management portfolio.

    Mark Vickery headshot

    Top Stock Reports for Johnson & Johnson, Chevron & Adobe

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Chevron (CVX) and Adobe (ADBE).

    VREX or BSX: Which Is the Better Value Stock Right Now?

    by Zacks Equity Research

    VREX vs. BSX: Which Stock Is the Better Value Option?